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theOBJECTIVES The purpose of this study was to investigate if systolic myocardial function is reduced in all patients with
type 1 diabetes (T1DM) or only in patients with albuminuria.
BACKGROUND Heart failure is a common cause of mortality in T1DM, and a speciﬁc diabetic cardiomyopathy has been
suggested. It is not known whether myocardial dysfunction is a feature of T1DM per se or primarily associated with
diabetes with albuminuria.
METHODS This cross-sectional study compared 1,065 T1DM patients without known heart disease from the outpatient
clinic at the Steno Diabetes Center with 198 healthy control subjects. Conventional echocardiography and global
longitudinal strain (GLS) by 2-dimensional speckle-tracking echocardiography was performed and analyzed in relation
to normoalbuminuria (n ¼ 739), microalbuminuria (n ¼ 223), and macroalbuminuria (n ¼ 103). Data were analyzed in
univariable and multivariable linear regression models adjusted for confounding factors including conventional risk
factors, medication, and systolic and diastolic dysfunction. Investigators were blinded to degree of albuminuria.
RESULTS Mean age was 49.5 years, 52% men, mean glycated hemoglobin 8.2% (66 mmol/mol), mean body mass index
25.5 kg/m2, and mean diabetes duration 26.1 years. In unadjusted analyses, GLS differed signiﬁcantly between T1DM
patients and control subjects (p ¼ 0.02). When stratiﬁed by degrees of albuminuria, the difference in GLS compared with
control subjects was 18.8  2.5% versus 18.5  2.5% for normoalbuminuria (p ¼ 0.28), versus 17.9  2.7% for
microalbuminuria (p ¼ 0.001), and versus 17.4  2.9% for macroalbuminuria (p < 0.001). Multivariable analyses,
including clinical characteristics, diastolic and systolic dysfunction, and use of medication, did not change this
relationship.
CONCLUSIONS Systolic function assessed by GLS was reduced in T1DM compared with control subjects. This differ-
ence, however, was driven solely by decreased GLS in T1DM patients with albuminuria. T1DM patients with normoal-
buminuria have systolic myocardial function similar to healthy control subjects. These ﬁndings do not support the
presence of speciﬁc diabetic cardiomyopathy without albuminuria. (J Am Coll Cardiol Img 2015;8:400–10)
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AB BR E V I A T I O N S
AND ACRONYM S
CAD = coronary artery disease
CVD = cardiovascular disease
GLS = global
longitudinal strain
LVMI = left ventricular
mass index
T1DM = type 1
diabetes mellitus
T2DM = type 2
tes mellitus
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401C ardiovascular disease (CVD) is one of themost common comorbidities and causes ofdeath in diabetes (1). Early identiﬁcation of
patients at particular risk is, therefore, of major
importance in the day-to-day clinical setting.
Currently, the most well-known heart disease in
diabetes is the premature development of coronary
atherosclerosis, which leads to ischemic heart dis-
ease; however, a special subset of heart failure in
diabetes has been proposed: the diabetic cardiomy-
opathy, which is the impairment of myocardial
function without major coronary vessel disease (2,3).
Diabetic cardiomyopathy is believed to be associated
with nephropathy, which is a common complication
in diabetes.
Type 1 diabetes mellitus (T1DM) is associated with
incidence rates of heart failure comparable to a
10-year-older background population, and the risk of
death due to CVD is increased 6- to 12-fold (4,5). So
far, studies of a possible diabetic cardiomyopathy
have been small and primarily in patients with type 2
diabetes (T2DM) (3). T1DM, however, may be a better
patient category to study because the myocardial
changes associated with T1DM are the result of a lack
of insulin and are, to a lesser degree than in T2DM,
confounded by lifestyle factors.SEE PAGE 411Speckle-tracking echocardiography is an imaging
technique developed as a method to objectively
quantify myocardial function and provides informa-
tion about myocardial strain (6). In the clinical
setting, left ventricular systolic function is usually
assessed visually or by Simpson’s biplane method.
Assessment of global ventricular longitudinal func-
tion using speckle-tracking imaging may, however, be
able to identify discrete changes that are not detect-
able with conventional echocardiography. Studies in
patients with heart failure and ischemic heart disease
have shown that impaired global longitudinal strain
(GLS) is associated with adverse events and provides
incremental prognostic information beyond conven-
tional echocardiography (7–9).
In the present study, we investigated the rela-
tionship between GLS and degrees of albuminuria
in T1DM patients without known heart disease
randomly selected from an outpatient clinic com-
pared with healthy control subjects. The aim of theSquibb, Eli Lilly, Janssen, Novo Nordisk, and Astellas; has received grants and
and Abbott; has received payment for lectures by AstraZeneca/Bristol-Myers
Nordisk. All other authors have reported that they have no relationships rel
Manuscript received October 17, 2014; revised manuscript received Novembpresent study was to examine if T1DM per se
is associated with reduced myocardial sys-
tolic function or if reduced myocardial func-
tion is a feature of concomitant albuminuria,
that is, to examine if diabetic cardiomyopa-
thy exists without the presence of albumin-
uria in T1DM.
METHODS
STENO DIABETES CENTER AND DEPARTMENT
OF CARDIOLOGY, COPENHAGEN UNIVERSITYHOSPITAL GENTOFTE. The Steno Diabetes Center is an
integrated part of the Danish public health care sys-
tem, and 90% of the patients are referred from the
Copenhagen Capital Region. The total number of pa-
tients followed at Steno Diabetes Center is around
6,000, of whom 3,500 patients have T1DM and the
remaining patients have T2DM. T1DM patients are
followed lifelong, with outpatient visits approxi-
mately every third month.
The Department of Cardiology, Copenhagen Uni-
versity Hospital Gentofte, is an invasive center with
a core echocardiography laboratory that performs
more than 6,400 echocardiographic examinations
annually.
STUDY POPULATION. The Thousand & 1 study is
a cross-sectional cohort study of T1DM patients
without known heart disease.
Invitation, screening, and inclusion of patients
started April 1, 2010, and inclusion was completed
April 1, 2012. Patients were eligible if they were
18 years or older, attending the outpatient clinic
at Steno Diabetes Center, diagnosed with T1DM,
without known heart disease, and willing to par-
ticipate. Known heart disease was deﬁned as heart
failure; coronary artery disease (CAD), including
previous myocardial infarction, stable angina, previ-
ous percutaneous coronary intervention, or coronary
artery bypass surgery; atrial ﬁbrillation or atrial
ﬂutter; left bundle branch block; congenital heart
disease; and pacemaker or implantable cardioverter-
deﬁbrillator insertion, all of which were exclusion
criteria. No ﬁnancial compensation was offered to
patients for their participation. The study population
and study visit has been described in detail elsewhere
(10). As previously shown, the included study popu-
lation was representative of T1DM patients without
diabe/or has grants pending from Novo Nordisk, Novartis,
Squibb, Novartis, and Sanoﬁ; and has stock in Novo
evant to the contents of this paper to disclose.
er 26, 2014, accepted December 1, 2014.
TABLE 1 Demographics, T1DM Versus Control Subjects
Thousand & 1
T1DM
(n ¼ 1,065)
CCHS 5
Control Subjects
(n ¼ 198)
T1DM vs.
Control Subjects
p Value*
Age, yrs 49.5  14.5 48.7  14 0.49
Male 52.1 52.0 0.98
Body mass index, kg/m2 25.5  3.9 24.5  3.2 <0.001
Ever smoker 56.2 55.1 0.76
Systolic blood pressure, mm Hg 133  17 130  12 0.002
Diastolic blood pressure, mm Hg 74  10 78  8 <0.001
Diabetes duration, yrs 26.1  15.7 NA NA
HbA1c NA NA
% 8.2  1.3
mmol/mol 66  14
eGFR, ml/min/1.73 m2 87  22 NA NA
Echocardiography
Left ventricular ejection fraction, % 58  5 61  5 <0.001
Left ventricular ejection fraction <45% 1.6 0.0 0.073
Dimensions
Left ventricular internal diameter, cm 4.5  0.5 4.7  0.5 <0.001
Septal wall, cm 0.9  0.2 0.9  0.1 0.24
Posterior wall, cm 0.9  0.2 0.9  0.1 <0.001
E peak, m/s 0.9  0.2 0.7  0.2 <0.001
A peak, m/s 0.7  0.2 0.6  0.2 <0.001
E/A ratio 1.26  0.5 1.46  0.6 <0.001
E deceleration time, ms 195  44 190  41 0.18
e0Lat, cm/s 12  4 14  4 <0.001
Diastolic dysfunction, E/e0Lat >12 7.6 1.0 0.001
Left atrial volume index, ml/m2 30  7 30  7 0.27
Left ventricular mass index, g/m2 71  15 73  13 0.04
Statins 43.2 Nil NA
Beta-blockers 4.6 Nil NA
ACE inhibitors/ATII antagonists 45.6 Nil NA
Calcium antagonists 18.9 Nil NA
Diuretics 25.9 Nil NA
Values are mean  SD or %. *p value between T1DM patients and control subjects using Student t test for
continuous variables and chi-square test for categorical variables.
A ¼ atrial inﬂow velocity; ACE ¼ angiotensin-converting enzyme; ATII ¼ angiotensin II; CCHS ¼ Copenhagen
City Heart Study; E ¼ diastolic mitral early inﬂow velocity; e0 ¼ pulsed-wave early diastolic tissue Doppler
velocities; eGFR ¼ estimated glomerular ﬁltration rate; HbA1c ¼ glycated hemoglobin; Lat ¼ lateral; NA ¼ not
applicable; Nil ¼ nothing; T1DM ¼ type 1 diabetes mellitus.
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402known heart disease followed at Steno Diabetes
Center without any major selection bias.
The study was performed in accordance with the
second Helsinki declaration and was approved by
the regional ethics committee (H-3-2009-139) and the
Danish Data Protection Agency (00934-Geh-2010-
003). All subjects gave written informed consent.
STUDY VISIT. Prior to the echocardiographic exami-
nation, all patients received study information,
signed the consent form, and ﬁlled out a question-
naire with information about lifestyle factors,
including smoking, exercise, alcohol consumption,
cardiorespiratory symptoms, and use of medication.
Blood pressure and electrocardiogram at rest were
recorded in the supine position.CONTROL POPULATION. A healthy, nondiabetic
control population was sampled from the ﬁfth cross-
sectional survey of the CCHS (Copenhagen City
Heart Study), which is currently in the inclusion
phase. The CCHS is a prospective cardiovascular
study of the general population (11). In the present
ﬁfth survey, subjects are invited if they have previ-
ously been invited to earlier cross-sectional surveys
of the CCHS; subjects are also randomly selected
through the Civil Registration System and invited to
participate to include up to 5,000 subjects for the
present survey. So far, around 2,500 patients have
been included since 2011.
After relevant approval from the steering commit-
tee of the CCHS was obtained, a total of 200 subjects
with similar age and sex distribution were included
as control subjects if they had no history of CVD in
the National Patient Registry; answered “No” to
previous CVD on the questionnaire; did not take any
cardiovascular medication; did not have diabetes;
did not have known kidney disease; did not have
known hypertension; and had an echocardiog-
raphy performed with the examination stored in the
EchoPac BT11 (GE Healthcare, Little Chalfont, United
Kingdom) format, a format which was replaced by
EchoPac BT12 in 2012. Subjects who met these criteria
were stratiﬁed consecutively by inclusion date in
5-year age and sex strata and sampled to reﬂect age
and sex distributions, similar to the T1DM patients.
Characteristics are shown in Table 1. Echocardiograms
were analyzed off-line by 1 investigator (M.T.J.)
using the same methodology as for the Thousand & 1
population described in the following text.
ECHOCARDIOGRAPHY. Echocardiography was per-
formed with a General Electric, Vivid 7 Dimension
imaging system device (GE Vingmed Ultrasound
AS, Horten, Norway) with a 3.5-MHz transducer in
accordance with the recommendations from the Eu-
ropean Association of Echocardiography/American
Society of Echocardiography (12). Echocardiographic
examinations were read and analyzed using General
Electric EchoPac software (BT11). Three consecutive
heart cycles were recorded. Left ventricular ejection
fraction was determined by Simpson’s biplane
method. Left atrial volume was determined by the
recommended biplane area-length method and
indexed for body surface area. Left ventricular mass
was determined by the linear method and indexed
for body surface area. Pulsed-wave Doppler was per-
formed in the apical 4-chamber view, with the sample
volume placed between the mitral leaﬂet tips to
obtain diastolic mitral early (E) and atrial (A) inﬂow
velocities and deceleration time of the E velocity
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403wave. Pulsed-wave early diastolic tissue Doppler
velocities (e0) were determined from the apical
4-chamber view at the lateral region of the mitral
annulus (13).
GLOBAL LEFT VENTRICULAR LONGITUDINAL STRAIN.
Global left ventricular longitudinal strain (GLS)
was measured using 2-dimensional speckle-tracking
echocardiography, where deformation of the left
ventricle is determined by tracking speckles from
frame to frame (Figure 1). First, the timing of aortic
valve closure is deﬁned. Thereafter, 3 points are
anchored inside the myocardial tissue at the mitral
valve plane as well as apically to allow for semi-
automated tracking. The tracking algorithm follows
the endocardium from a single frame throughout
the cardiac cycle and allows for a further manual
adjustment of the region of interest to ensure that
all myocardial regions are included and tracked
accurately throughout the cardiac cycle. Accurate
tracking is ensured by visual evaluation of tracking
and segmental strain curves. Apical images of the 2-,
3-, and 4-chamber views of the left ventricle are
divided into 6 segments (basal, mid, and apical seg-
ments in opposing walls), and the tracking quality of
each of the 18 segments are manually approved or
rejected. The algorithm subsequently calculates a
strain score for each apical view. The method has
been described in detail elsewhere (6,14,15). For the
present analysis, GLS was determined as the
average of the 3 apical views, thereby providing a
GLS measure for the entire left ventricle. Conse-
quently, only patients who had information from all
3 apical views available were included in the
analysis, thus excluding 28 patients (2.6%). For the
included 1,065 patients, overall feasibility was
96.6%. Images were obtained at a mean frame rate
of 76 frames/s.
All echocardiographic examinations were perfor-
med, read, and analyzed by Dr. Jensen, and were
validated with a second opinion by another ex-
perienced imaging cardiologist. Interobserver and
intraobserver variability was assessed with 25
randomly selected patients and showed good agree-
ment with no systematic bias. For Simpson’s biplane,
left ventricular ejection fraction limits of agreement
were (mean of difference2 SD)0.6% (11.0 10.0%)
for interobserver variability and 0.6% (9.0  7.0%)
for intraobserver variability (Bland-Altman plots
not shown) (16), and the GLS interobserver and intra-
observer variability was 0.18% (1.9  1.5%) and
0.12% (1.5  1.3%), respectively.
BIOCHEMISTRY. Information about biochemistry, such
as glycated hemoglobin, p-creatinine, and albuminuricstatus, was collected from electronic patient ﬁles
at Steno Diabetes Center from the ambulatory visit
closest to study inclusion, which was maximally
4 months from inclusion. This information was
collected after analyzing the echocardiogram, en-
suring that the investigators were blinded.
Urinary albumin excretion rate (UAER) was
measured in 24-h sterile urine collections by enzyme
immunoassay. Patients were categorized as nor-
moalbuminuric if UAER, in 2 of 3 consecutive mea-
surements, was <30 mg/24 h, microalbuminuric if
UAER was between 30 and 300 mg/24 h, and macro-
albuminuric if UAER was >300 mg/24 h. Glycated
hemoglobin was measured by high-performance
liquid chromatography (Variant, Bio-Rad Labora-
tories, Munich, Germany) (normal range 21 to 46
mmol/mol [4.1% to 6.4%]) and serum creatinine
concentration by an enzymatic method (Hitachi
912, Roche Diagnostics, Mannheim, Germany). Esti-
mated glomerular ﬁltration rate was calculated by
the MDRD (Modiﬁcation of Diet in Renal Disease)
method (17).
STATISTICAL ANALYSIS. All analyses were per-
formed with STATA version 12.1 (STATACorp LP,
College Station, Texas). Categorical variables were
analyzed with the chi-square test and continuous
variables with analysis of variance or the Student
t test.
GLS was studied in T1DM patients versus control
subjects with similar age and sex distribution, and in
T1DM patients by degree of albuminuria versus con-
trol subjects. Four different models were performed:
an unadjusted model; a multivariable model (model 1)
including baseline characteristics and adjustments for
systolic and diastolic dysfunction as well as left
ventricular mass index (LVMI); a multivariable model
(model 2) including the same variables as model 1
but excluding patients with systolic dysfunction;
and a multivariable model (model 3) including the
same variables as in model 2 but also including use
of medication. Baseline characteristics included age,
sex, body mass index, smoking status, systolic blood
pressure, diastolic blood pressure, LVMI, and systolic
and diastolic dysfunction. Age and sex were included
in the analyses stratiﬁed by degree of albuminuria but
were not included when analyzing the T1DM patients
compared with the control subjects because the
control subjects were matched by age and sex.
Smoking status and blood pressure are well-known
risk factors of CVD, and LVMI was included
because it is an overall indicator of cardiac remodel-
ing. Systolic dysfunction was deﬁned as left ventric-
ular ejection fraction <45%, and diastolic dysfunction
FIGURE 1 Global Longitudinal Strain
Bull’s-eye plot of global longitudinal strain (GLS) and 3 apical projections; apical 4-chamber shown in end-systole with endocardial
tracking, 2-chamber and apical long-axis views shown in end-diastole. Patient A, a 44-year-old male patient with type 1 diabetes mellitus
with normoalbuminuria, normal left ventricular ejection fraction, normal ventricular dimensions, and normal atrial size. GLS ¼ 25.7%.
Patient B, a 45-year-old male patient with type 1 diabetes mellitus with macroalbuminuria, normal left ventricular ejection fraction,
normal ventricular dimensions, and normal atrial size. GLS ¼ 17.7%. ANT ¼ anterior; INF ¼ inferior; LAT ¼ lateral; POST ¼ posterior;
SEPT ¼ septal.
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405was deﬁned as E/e0 lateral >12 because this measure has
been shown to be the best indicator of diastolic
dysfunction (18). To account formultiple comparisons in
the baseline characteristics of between-albuminuria-
group differences, a p value <0.017 (Bonferroni) was
considered statistically signiﬁcant in these analyses
(Table 2). A p value <0.05 was considered statistically
signiﬁcant unless otherwise stated.RESULTS
BASELINE CHARACTERISTICS. A total of 1,065 pa-
tients with complete information on GLS and albu-
minuria were included; 739 patients were classiﬁed
as having normoalbuminuria, 223 patients as micro-
albuminuria, and 103 patients as macroalbuminuria.TABLE 2 Demographics, T1DM Stratiﬁed by Degree of Albuminuria
Type 1 Diabe
Normoalbuminuria Microa
N, % 739 (69.4) 223
Age, yrs 47.8  14.8 54.4
Male 50.2 5
Body mass index, kg/m2 25.3  3.7 25.9
Ever smoker 53.5 6
Systolic blood pressure, mm Hg 131  16 136
Diastolic blood pressure, mm Hg 74  9 73
Diabetes duration, yrs 22.8  15.0 32.7
HbA1c
% 8.1  1.3 8.3
mmol/mol 65  14 67
eGFR, ml/min/1.73 m2 91  19 85
Echocardiography
Left ventricular ejection fraction, % 58  5 57
Left ventricular ejection fraction <45% 1.5
Dimensions
Left ventricular internal diameter, cm 4.6  0.5 4.5
Septal wall, cm 0.9  0.1 0.9
Posterior wall, cm 0.9  0.2 0.9
E peak, m/s 0.8  0.2 0.9
A peak, m/s 0.7  0.2 0.8
E/A ratio 1.31  0.5 1.15
E deceleration time, ms 193  41 201
E0Lat, cm/s 13.1  4.0 11.4
Diastolic dysfunction, E/e0Lat >12 3.9 1
Left atrial volume index, ml/m2 29  6 30
Left ventricular mass index, g/m2 70  14 72
Statins 34.4 5
Beta-blockers 1.5
ACE inhibitors/ATII antagonists 32.9 7
Calcium antagonists 11.6 2
Diuretics 16.8 3
Values are n (%), mean  SD, or %. *p values using analysis of variance for continuous va
Macro ¼ macroalbuminuria; Micro ¼ microalbuminuria; Normo ¼ normoalbuminuria; oIn addition, 198 sex- and age-matched healthy control
subjects with GLS were included. Demographics are
shown in Tables 1 and 2.
Echocardiographic characteristics. Echocardiographic
baseline characteristics are presented in Tables 1
and 2. LV dimensions were signiﬁcantly different
between groups of albuminuria. Transmitral Doppler
E/A ratio decreased with increasing degree of albu-
minuria. Also, tissue Doppler early diastolic velocity,
e0, decreased, and an E/e0 >12 was more prevalent
with increasing degree of albuminuria. In the T1DM
population, 1.6% of the population had systolic
dysfunction compared with none of the control
subjects.
GLS IN T1DM VERSUS CONTROL SUBJECTS. Women
had greater strain values than men; in the Thousandtes (n ¼ 1,065) p Values
lbuminuria Macroalbuminuria
Albuminuria
Groups*
Normo- vs.
Micro-*†
Normo- vs.
Macro-*†
Micro- vs.
Macro-*†
(20.9) 103 (9.7)
 13.6 50.7  11.2 <0.001 <0.001 0.036 0.025
5.6 58.3 0.16 0.16 0.13 0.65
 4.1 26.1  4.4 0.04 0.053 0.045 0.63
1.4 64.1 0.025 0.036 0.042 0.65
 17 140  19 <0.001 <0.001 <0.001 0.038
 11 75  11 0.18 0.14 0.36 0.13
 15.8 35.7  11.3 <0.001 <0.001 <0.001 0.042
<0.001 0.070 <0.001 <0.001
 1.1 8.8  1.3
 12 73  14
 23 64  29 <0.001 <0.001 <0.001 <0.001
 5 58  6 0.48 0.25 0.99 0.51
1.4 2.9 0.53 0.88 0.29 0.21
 0.4 4.4  0.5 <0.001 0.002 0.002 0.41
 0.2 1.0  0.2 <0. 001 <0.001 <0.001 0.002
 0.2 1.0  0.2 <0.001 <0.001 <0.001 <0.001
 0.2 0.9  0.2 <0.001 0.005 <0.001 0.10
 0.2 0.9  0.2 <0.001 <0.001 <0.001 0.06
 0.4 1.11  0.4 <0.001 <0.001 <0.001 0.56
 46 196  50 0.048 0.012 0.70 0.25
 3.8 10.1  3.2 <0.001 <0.001 <0.001 0.005
3.0 22.3 <0.001 <0.001 <0.001 0.033
 6 32  8 0.002 0.22 <0.001 0.008
 15 78  18 <0.001 0.044 <0.001 0.009
7.4 75.7 <0.001 <0.001 <0.001 0.001
8.1 19.4 <0.001 <0.001 <0.001 0003
0.0 84.5 <0.001 <0.001 <0.001 0.005
9.2 48.5 <0.001 <0.001 <0.001 0.001
6.3 68.9 <0.001 <0.001 <0.001 <0.001
riables and chi-square test for categorical variables. †p ¼ 0.017 was considered statistically signiﬁcant (Bonferroni).
ther abbreviations as in Table 1.
TABLE 3 GLS in T1D
T1DM vs. Control Su
Age- and Sex-Mat
GLS
Systolic blood pressure
Diastolic blood pressur
Body mass index, unit
Ever smoker
Left ventricular mass in
Diastolic dysfunction, E
Systolic dysfunction, L
Use of statins
Use of beta-blockers
Use of calcium-channe
Use of ACE or ATII inhi
Use of diuretics
Unadjusted: GLS in 1,065 T
diastolic dysfunction, and s
blood pressure, body mass
subjects). Adjusted for sys
GLS ¼ global longitudin
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406& 1 study: women 19.1  2.6% versus men 17.6 
2.4%, p < 0.001; in control subjects: women 19.7 
2.3% versus men 17.9  1.9%, p < 0.001.
The population mean values of GLS were 18.3%
for the T1DM patients and 18.8% for the control
subjects, and this difference was signiﬁcant (p ¼ 0.02)
(Table 3). In multivariable model 1, the estimate
was essentially unchanged. The differences persisted
when excluding patients with systolic dysfunction,
as shown in model 2. When including use of medi-
cation (model 3), none of the medications reached
statistical signiﬁcance in relation to GLS. The inclu-
sion of the medication variables, however, attenu-
ated the observed difference in GLS between T1DM
patients and control subjects (Table 3).
GLS IN T1DM BY DEGREE OF ALBUMINURIA VERSUS
CONTROL SUBJECTS. The patient population was
stratiﬁed by degrees of albuminuria. Values
were 18.5  2.5% for patients with normoalbumi-
nuria, 17.9  2.7% for patients with microal-
buminuria, and 17.4  2.9% for patients with
macroalbuminuria. As shown in Table 4, GLS did not
differ between control subjects and T1DM patients
with normoalbuminuria, but differences were highly
signiﬁcant between control subjects and patients
with microalbuminuria (p ¼ 0.001) and macro-
albuminuria (p < 0.001). In the multivariable models
(models 1, 2, and 3) the estimates changed only
slightly when including baseline characteristics, sys-
tolic and diastolic function, and use of medication.M Versus Control Subjects
bjects,
ched
Unadjusted
Multivariable
Model 1
b-Coefﬁcient
(95% CI) p Value
b-Coefﬁcient
(95% CI) p Value
0.46 (0.07 to 0.85) 0.02 0.40 (0.03 to 0.78) 0.036
, mm Hg 0.0002 (0.01 to 0.01) 0.97 
e, mm Hg 0.031 (0.11 to 0.18) <0.001
0.15 (0.11 to 0.18) <0.001
0.45 (0.18 to 0.71) 0.001
dex, g/m2 0.020 (0.01 to 0.03) <0.001
/e0Lat >12 0.71 (0.16 to 1.26) 0.012
VEF <45% 3.77 (2.6 to 4.9) <0.001
l blockers
bitors
1DM versus 198 control subjects. Multivariable model 1: adjusted for systolic blood pressu
ystolic dysfunction. Multivariable model 2: includes only patients with normal systolic functi
index, smoking, left ventricular mass index, and diastolic dysfunction. Multivariable mode
tolic blood pressure, diastolic blood pressure, body mass index, smoking, left ventricular m
al strain; other abbreviations as in Table 1.Use of any of the medications was not independently
associated with GLS. In a model where use of medi-
cation was included as a dichotomous variable, group
differences were similar to the multivariable model
3 where medications were included individually
(control subjects vs. normoalbuminuria, p ¼ 0.39;
control subjects vs. microalbuminuria, p ¼ 0.031; and
control subjects vs. macroalbuminuria, p ¼ 0.021).
DIASTOLIC DYSFUNCTION AND GLS. As shown in
the multivariate models 1, 2, and 3 (Tables 3 and 4),
diastolic dysfunction was independently associated
with decreased GLS. Inclusion of diastolic dysfunc-
tion in the multivariable models did not change the
relationship between albuminuria and reduced GLS
in patients with T1DM.
DISCUSSION
In the present study, 1,065 T1DM patients without
known heart disease were included from the outpa-
tient clinic at Steno Diabetes Center and compared
with 198 nondiabetic control subjects from the
currently ongoing ﬁfth cross-sectional survey of the
Copenhagen City Heart Study.
The concept of a speciﬁc diabetic cardiomyopathy
has received much attention (3,19,20). An important
question to answer in this respect is whether diabetes
per se is associated with myocardial impairment
or if impaired myocardial function is present only
in relation to concomitant complications, such asMultivariable
Model 2
Multivariable
Model 3
b-Coefﬁcient
(95% CI) p Value
b-Coefﬁcient
(95% CI) p Value
0.40 (0.03 to 0.78) 0.038 0.24 (0.16 to 0.64) 0.24
0.001 (0.01 to 0.009) 0.92 0.005 (0.01 to 0.006) 0.39
0.033 (0.017 to 0.05) <0.001 0.036 (0.019 to 0.05) <0.001
0.15 (0.11 to 0.19) <0.001 0.14 (0.11 to 0.18) <0.001
0.45 (0.18 to 0.72) 0.001 0.43 (0.16 to 0.70) 0.002
0.019 (0.01 to 0.03) <0.001 0.018 (0.01 to 0.03) <0.001
0.78 (0.22 to 1.35) 0.006 0.62 (0.045 to 1.20) 0.035
0.15 (0.19 to 0.48) 0.39
0.63 (0.11 to 1.37) 0.09
0.12 (0.57 to 0.32) 0.59
0.27 (0.09 to 0.64) 0.14
0.04 (0.37 to 0.46) 0.84
re, diastolic blood pressure, body mass index, smoking, left ventricular mass index,
on (n ¼ 1,048 vs. 198 control subjects). Adjusted for systolic blood pressure, diastolic
l 3: includes only patients with normal systolic function (n ¼ 1,048 vs. 198 control
ass index, diastolic dysfunction, and use of medication.
TABLE 4 GLS in T1DM by Degree of Albuminuria Versus Control Subjects
Unadjusted
Multivariable
Model 1
Multivariable
Model 2
Multivariable
Model 3
b Coefﬁcient
(95% CI) p Value
b Coefﬁcient
(95% CI) p Value
b Coefﬁcient
(95% CI) p Value
b Coefﬁcient
(95% CI) p Value
GLS
Control subjects vs.
normoalbuminuria
0.22 (0.18 to 0.62) 0.28 0.22 (0.15 to 0.59) 0.25 0.22 (0.15 to 0.60) 0.25 0.18 (0.22 to 0.58) 0.37
Control subjects vs.
microalbuminuria
0.85 (0.37 to 1.34) 0.001 0.64 (0.18 to 1.10) 0.007 0.63 (0.17 to 1.10) 0.008 0.56 (0.44 to 1.08) 0.034
Control subjects vs.
macroalbuminuria
1.33 (0.73 to 1.94) <0.001 0.86 (0.29 to 1.44) 0.003 0.83 (0.25 to 1.42) 0.005 0.69 (0.01 to 1.37) 0.045
Age, per 1-yr increase 0.005 (0.005 to 0.015) 0.29 0.006 (0.005 to 0.016) 0.28 0.004 (001 to 0.02) 0.44
Male 1.43 (1.15 to 1.72) <0.001 1.44 (1.16 to 1.73) <0.001 1.45 (1.16 to 1.73) <0.001
Systolic blood
pressure, mm Hg
0.003 (0.01 to 0.01) 0.56 0.003 (0.01 to 0.01) 0.50 0.004 (0.01 to 0.01) 0.47
Diastolic blood
pressure, mm Hg
0.032 (0.016 to 0.05) <0.001 0.033 (0.17 to 0.05) <0.001 0.033 (0.17 to 0.05) <0.001
Body mass index, kg/m2 0.14 (0.10 to 0.17) <0.001 0.14 (0.11 to 0.17) <0.001 0.14 (0.10 to 0.17) <0.001
Ever smoker 0.42 (0.16 to 0.68) 0.001 0.43 (0.17 to 0.69) 0.001 0.43 (0.17 to 0.70) 0.001
Left ventricular mass
index, g/m2
0.002 (0.01 to 0.01) 0.65 0.003 (0.01 to 0.01) 0.58 0.003 (0.01 to 0.01) 0.60
Diastolic dysfunction,
E/e0 >12
0.83 (0.28 to 1.39) 0.003 0.90 (0.33 to 1.47) 0.002 0.88 (0.31 to 1.45) 0.002
Systolic dysfunction,
LVEF <45%
3.60 (2.5 to 4.7) <0.001
Use of statins 0.13 (0.20 to 0.46) 0.44
Use of beta-blockers 0.48 (0.24 to 1.20) 0.19
Use of calcium-channel
blockers
0.22 (0.65 to 0.21) 0.31
Use of ACE or ATII inhibitors 0.004 (0.36 to 0.37) 0.98
Use of diuretics 0.09 (0.32 to 0.50) 0.66
Unadjusted: GLS in 1,065 T1DM stratiﬁed by degree of albuminuria (normo: n ¼ 739; micro: n ¼ 223; macro: n ¼ 103) versus 198 control subjects. Multivariable model 1: adjusted for age, sex, systolic blood
pressure, diastolic blood pressure, body mass index, smoking, left ventricular mass index, diastolic dysfunction, and systolic dysfunction. Multivariable model 2: includes only patients with normal systolic
function (n ¼ 1,048 [normo: n ¼ 728; micro: n ¼ 220; macro: n ¼ 100]). Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, body mass index, smoking, left ventricular mass index, and
diastolic dysfunction. Multivariable model 3: includes only patients with normal systolic function (n ¼ 1,048 [normo: n ¼ 728; micro: n ¼ 220; macro: n ¼ 100]). Adjusted for age, sex, systolic blood pressure,
diastolic blood pressure, body mass index, smoking, left ventricular mass index, diastolic dysfunction, and use of medication.
Abbreviations as in Tables 1, 2, and 3.
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407albuminuria and kidney disease. The ﬁndings of the
present study suggest that T1DM patients without
albuminuria have a systolic function that is similar
to a healthy background population. In the present
study, the observed difference in systolic myocardial
function measured by GLS between patients with
T1DM and healthy control subjects was driven alone
by reduced GLS in T1DM patients with albuminuria.
Thus, these ﬁndings do not support the concept
of a speciﬁc diabetic cardiomyopathy in patients
without albuminuria.
In the day-to-day clinical setting, the ﬁnding that
myocardial systolic function is reduced only in T1DM
patientswith albuminuria underscores the importance
of preventing, diagnosing, and treating T1DM patients
with kidney disease. It is well known that the presence
of albuminuria is a major risk factor for the develop-
ment of heart disease in T1DM, and albuminuria in
T1DM is associated with increased mortality. Further-
more, it appears that patients with T1DM but withoutalbuminuria have a prognosis that is similar to the
background population (21–23). This is in line with the
ﬁndings from the present study. As shown in this
study, 30% of the patients with microalbuminuria and
15% of the patients with macroalbuminuria did not
receive an angiotensin-converting enzyme inhibitor or
angiotensin II antagonist. The prevention of diabetic
kidney disease by ensuring proper renoprotective and
cardioprotective medication may be a feasible way of
preventing the reduction in myocardial function in
patients with T1DM.
In the present study, an association between
albuminuria and reduced myocardial function was
demonstrated. Here, a clear dose–response relation-
ship was found, as patients with macroalbuminuria
had lower GLS compared with patients with micro-
albuminuria. Although diastolic dysfunction was
associated with degree of albuminuria, the reduction
in GLS was independent of diastolic dysfunction. This
ﬁnding is interesting, as diastolic dysfunction is often
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408described as being the ﬁrst sign of diabetic cardio-
myopathy (3). The association between albuminuria
and risk of CVD and mortality has been shown in
several population studies, and albuminuria has been
shown to be 1 of the most important prognostic fac-
tors in diabetes (21,23,24). The association between
albuminuria, myocardial impairment, and adverse
events seems particularly strong for heart failure (25),
a disease entity which, in terms of complications with
diabetes, is receiving increasing attention (26,27).
Albuminuria is believed to be a marker of general
vascular damage (28), and microalbuminuria has
been shown to also be predictive of ischemic heart
disease in the general population (29). In line with
the increased incidence of diabetes and its compli-
cations, there has been increased focus on a possible
diabetic cardiomyopathy, which is myocardial dys-
function associated with diabetic nephropathy in
the absence of CAD (2,19,20,30). Several studies
support the ﬁndings of altered myocardial function
in patients with diabetes and in patients with kidney
disease (31). The underlying factors relate to changes
in the renin-angiotensin-aldosterone system (RAAS)
and arterial blood pressure, and treatment is,
therefore, primarily focused on RAAS inhibition
(32,33). Connelly et al. (34) have shown that hyper-
glycemia and the presence of kidney disease/
changes in the RAAS seem instrumental in the
development of diabetic cardiomyopathy. Here, we
found that these results can be translated from
studies in animals to clinical studies in ambulatory
patients.
GLS is a relatively new measure of systolic func-
tion and measures deformation, that is, systolic
contraction. Deformation imaging, or strain, has been
developed to detect subtle changes in systolic func-
tion. Speckle-tracking echocardiography was, there-
fore, used to detect possible reduction in systolic
function not detectable by conventional echocardi-
ography in patients with different degrees of albu-
minuria compared with a control population. Other
speckle-tracking measures, such as strain rate or
radial and circumferential strain, could possibly
expand our knowledge about cardiac mechanics
in T1DM (35); GLS, however, appears to show the
best reproducibility across different vendors, and
may, therefore, be the most robust marker of changes
in systolic function in the day-to-day clinical setting
(36). GLS has previously been shown to be able
to predict prognosis in patients with myocardial
infarction beyond conventional echocardiography (7)
and may be used as an addition to conventional
echocardiography in an extended cardiac evaluation
to detect discrete changes in myocardial function.STUDY LIMITATIONS. First, the current population
is the largest cohort of T1DM patients studied with
speckle-tracking echocardiography to date; it is,
therefore, possible to detect changes and study the
inﬂuence of several factors on myocardial function
not previously reported.
A limitation in the present study may be that
the presence of subclinical CAD was unknown, and
the few patients with systolic dysfunction may
represent undiagnosed CAD. The Thousand & 1 pop-
ulation, however, represents real-life ambulatory
patients without known heart disease. It is also worth
noting that these patients are followed every third
month at the Steno Diabetes Center throughout their
lives, and clinical signs or a history of cardiac symp-
toms will prompt further investigation. If these pa-
tients develop heart disease, there is a good chance
that it will be diagnosed. Also, indicating against
signiﬁcant CAD is the ﬁnding that patients with nor-
moalbuminuria had a systolic function comparable to
the control subjects. We performed multivariable
analyses both adjusting for and excluding patients
with systolic dysfunction, and this did not change the
overall results. A functional test or further studies of
possible CAD would, however, have strengthened the
ﬁndings further.
CONCLUSIONS
In the present study of 1,065 T1DM patients with-
out known heart disease compared with 198 nondia-
betic healthy control subjects, we found that systolic
function assessed by GLS is reduced in T1DM
compared with control subjects. The difference be-
tween groups, however, is driven solely by decreased
GLS in patients with albuminuria in that there is
no difference between control subjects and T1DM
patients with normoalbuminuria.
These ﬁndings suggest that reduced systolic
myocardial function in T1DM is associated primarily
with the presence of albuminuria. T1DM patients
with normoalbuminuria have systolic myocardial
function similar to healthy control subjects.
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PERSPECTIVES
COMPETENCY INMEDICAL KNOWLEDGE: Type 1
diabetes is not associated with systolic myocardial impair-
ment per se. Systolic myocardial impairment in type 1 dia-
betes occurs in associationwith the presenceof albuminuria.
Type 1 diabetes patients without albuminuria have a systolic
myocardial function similar to that of healthy controls.
TRANSLATIONAL OUTLOOK: Further studies of the
pathogenesis and prevention of heart disease in diabetes
are needed with special emphasis on patients with
albuminuria.
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